

UCSF

UC San Francisco Previously Published Works

Title

Lack of Equipoise in the PDA-TOLERATE Trial: A Comparison of Eligible Infants Enrolled in the Trial and Those Treated Outside the Trial

Permalink

<https://escholarship.org/uc/item/8rq093fw>

Authors

Liebowitz, Melissa
Katheria, Anup
Sauberan, Jason
[et al.](#)

Publication Date

2019-10-01

DOI

10.1016/j.jpeds.2019.05.049

Peer reviewed



Published in final edited form as:

J Pediatr. 2019 October ; 213: 222–226.e2. doi:10.1016/j.jpeds.2019.05.049.

Lack of Equipoise in the PDA-TOLERATE Trial: A Comparison of Eligible Infants Enrolled in the Trial and Those Treated outside the Trial

Melissa Liebowitz, MD¹, Anup Katheria, MD², Jason Sauberan, PharmD², Jaideep Singh, MD³, Kelly Nelson, MD³, Denise C. Hassinger, MD⁴, Susan W. Aucott, MD⁵, Joseph Kaempf, MD⁶, Amy Kimball, MD⁷, Erika Fernandez, MD⁷, William A. Carey, MD⁸, Jorge Perez, MD⁹, Arturo Serize, PA⁹, Andrea Wickremasinghe, MD¹⁰, Lawrence Dong, MD¹⁰, Matthew Derrick, MD¹¹, Ilene Sue Wolf, RN¹¹, Anne Marie Heuchan, MD¹², Meera Sankar, MD¹³, Ali Bulbul, MD¹⁴, Ronald I. Clyman, MD^{1,15}, PDA-TOLERATE (PDA: TOLEave it alone or Respond And Treat Early) Trial Investigators*

¹Department of Pediatrics, University of California San Francisco, San Francisco, CA

²Department of Pediatrics, Sharp Mary Birch Hospital for Women and Newborns, San Diego, CA

³Department of Pediatrics, University of Chicago, Chicago, IL

⁴Department of Pediatrics, Morristown Medical Center, Morristown, NJ

⁵Department of Pediatrics, Johns Hopkins University, Baltimore, MD

⁶Department of Pediatrics, Providence St. Vincent Medical Center, Portland, OR

⁷Department of Pediatrics, University of California San Diego and Rady Children's Hospital, San Diego, CA

⁸Department of Pediatrics, Mayo Clinic, Rochester, MN

⁹Department of Pediatrics, South Miami Hospital/Baptist Health South Florida, Miami, FL

¹⁰Department of Pediatrics, Kaiser Permanente Medical Center, Santa Clara, CA

¹¹Department of Pediatrics, Northshore University Health System, Evanston, IL

¹²Department of Pediatrics, University of Glasgow, Royal Hospital for Sick Children, Glasgow, Scotland, UK

¹³Department of Pediatrics, Mednax Medical Group, Good Samaritan Hospital, San Jose, CA

¹⁴Department of Pediatrics, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey

¹⁵Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA

*List of additional PDA-TOLERATE investigators is available at www.jpeds.com (Appendix)

Address for correspondence: Ronald Clyman, MD, University of California San Francisco, 513 Parnassus Ave., UCSF Box 0734, San Francisco, CA 94143-0734; phone:415-353-1565; clymanr@peds.ucsf.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Abstract

The PDA-TOLERATE trial compared the effects of 2 strategies for treatment of patent ductus arteriosus (PDA) in infants <28^{0/7} weeks gestation; however 137 potentially eligible infants were not recruited and received treatment of their PDA outside the PDA-TOLERATE trial due to “lack-of-physician-equipose” (LPE). Despite being less mature and needing more respiratory support, LPE infants had less mortality than enrolled infants. LPE infants treated before day 6 had less late respiratory morbidity than LPE infants treated day 6.

Trial registration—[Clinicaltrials.gov](https://clinicaltrials.gov):

Keywords

premature birth; bronchopulmonary dysplasia; patent ductus arteriosus

PDA-TOLERATE (NCT01958320) was a multi-center, randomized, controlled trial that compared the effects of 2 strategies for treatment of patent ductus arteriosus (PDA) in infants <28^{0/7} weeks gestation (1). The trial enrolled 202 infants with moderate-to-large PDA who required respiratory support. Infants were randomized at the end of the first week to receive either routine pharmacologic treatment or a conservative approach that delayed pharmacologic treatment until pre-specified respiratory and/or cardiovascular “rescue” criteria were met. The trial demonstrated that routine PDA treatment at the end of the first week did not reduce PDA ligations or presence of a PDA at discharge, nor did it reduce any of the pre-specified secondary outcomes (death, bronchopulmonary dysplasia [BPD], or BPD or death prior to 36 weeks).

Physicians caring for infants in the PDA-TOLERATE trial stated before joining the trial that they had equipoise regarding the risks and benefits of each of the trial’s therapeutic arms and were willing to recruit and enroll all eligible infants. However, 18% of potentially eligible infants were not recruited into the trial due to the medical team’s desire to use pharmacologic PDA treatment outside the confines of the trial (*lack of physician equipoise* [LPE]). In these cases, the physicians elected to exclude the infants from the trial and treat them either because of a perceived risk associated with randomization to the conservative approach or because they felt the infants were “too sick to wait” for randomization at the end of the first week.

Because these potentially eligible infants were excluded from the trial, we designed the following study to determine if the infants enrolled in PDA-TOLERATE really reflected the population of infants the trial was designed to examine (namely, those <28^{0/7} weeks gestation with moderate-to-large PDA). We wanted to determine whether infants treated outside the trial, due to LPE, differed from those enrolled in the trial, both in their early clinical characteristics and in their ultimate clinical outcomes. We hypothesized that infants who were excluded due to LPE would be less mature and “sicker” than those who were enrolled in PDA-TOLERATE and would be at greater risk for developing neonatal morbidity.

Methods

Our observational study utilized data from two study data sets; data from infants enrolled in PDA-TOLERATE (a prospective randomized controlled trial conducted between January 2014 and June 2017 at 17 international sites (1)) and data from infants screened for PDA-TOLERATE who were excluded from the trial (even though they were potentially eligible) because the medical team wanted to use pharmacologic PDA treatment outside the confines of the study. Institutional review board approvals were obtained at the study sites for both the parent PDA-TOLERATE trial and the ancillary study examining patients not enrolled due to LPE.

Full details of PDA-TOLERATE including screening, echocardiographic analyses, inclusion and exclusion criteria, enrollment and drug treatment protocols, and definitions of study variables and outcomes have been published elsewhere (1). Infants <28^{0/7} weeks gestation were enrolled in PDA-TOLERATE if they were between 6–14 days old, had a moderate-to-large PDA, and were receiving greater than minimal respiratory support defined as either positive pressure ventilation, continuous positive airway pressure, or high flow nasal cannula support with >2 L/min cannula flow and FiO₂ >0.25 (1).

Eligible infants were excluded from participation if they received treatment with indomethacin or ibuprofen prior to randomization, had chromosomal anomalies, congenital or acquired gastrointestinal anomalies, prior episodes of necrotizing enterocolitis or intestinal perforation, active pulmonary hemorrhage at the time of enrollment, or contraindications to the use of indomethacin or ibuprofen (e.g., hydrocortisone or dexamethasone administration within preceding 24 hours, urine output < 1 ml/kg/h during preceding 8 hours, serum creatinine >1.6 mg/dl, platelet count <50, 000/mm³, or abnormal coagulation studies). Sixteen of the 17 centers also excluded infants if they needed inotropic support for hypotension at the time of enrollment (1). Except for the difference in timing of PDA treatment, the two arms of the study used the same treatment protocols at each site for feeding advances, ventilator management, fluid management, or management of hypotension.

Study coordinators, who were not blinded to the patients' treatment assignments, collected information from infants enrolled in PDA-TOLERATE and all eligible infants who were excluded from the trial due to LPE. All variables were defined a-priori before data extraction. The reasons given during interviews with the medical teams for not enrolling the infants and excluding them from the trial were either: "this infant is too sick and I don't want to wait until 6 days before starting treatment," or "this infant should be treated and I do not want to risk the possibility that he/she could be randomized to the conservative approach." Infants who were treated outside of the trial due to LPE had echocardiographic assessments to confirm the presence of a moderate-to-large PDA and received the same drug treatment protocol used in PDA-TOLERATE at that site (1).

Two hundred and two infants were enrolled in PDA-TOLERATE; 152 were treated outside of the trial due to LPE. Sixteen of the 17 sites submitted data for patients at their site who were not enrolled due to LPE (n=137). One site, that enrolled only two patients in PDA-

TOLERATE, was unable to furnish data for the 15 patients at that site who were not enrolled due to LPE.

Statistical analyses

Our primary goal was to compare the demographic variables and neonatal outcomes between infants who were treated outside PDA-TOLERATE (due to LPE) and those that were enrolled in the trial. *Stata Statistical Software: Release 14* (StataCorp. 2015. College Station, TX: StataCorp LP) was used for all statistical analysis. Chi-Squared tests were used to compare categorical variables, Student t-tests were used to compare parametric variables, and Wilcoxon rank sum tests were used to compare non-parametric variables. *P* values <0.05 were considered to be significant.

Among infants treated outside the trial due to LPE, we also used logistic regression to examine the relationship between the age at PDA treatment and neonatal morbidity. To perform this analysis we created statistical models that included our variable of interest (*Postnatal age at treatment*) in addition to the other demographic variables that have been associated with the outcome of interest (“BPD or Death”): *Betamethasone 24 hours, Small for Gestational Age, Caucasian race, Intubation at 24 hours, Dopamine during first 72 hours after birth, early onset bacteremia, and late onset bacteremia*. To determine which of these demographic variables should be included in the Final statistical model we first performed a logistic regression to determine the odds ratio for our variable of interest (*Postnatal age at treatment*) alone (Basic Model). Next, we added one of the other demographic variables to the Basic Model and re-ran the logistic regression to determine to what extent the odds ratio for the variable *Postnatal age at treatment* was altered by the addition of the new variable. If the addition of the new variable altered the odd’s ratio of *Postnatal age at treatment* by more than 10% we considered it to be an *important demographic variable* that should be added to the final adjusted model. We repeated this step with each of the other demographic variables. The final adjusted model contained the variables *Postnatal age at treatment* plus *Gestational Age* plus all of the other *important demographic variables*.

Results

Infants who were treated outside PDA-TOLERATE due to LPE were significantly younger; less likely to have received antenatal betamethasone; more likely to have needed surfactant; and more likely to have needed intubation during the first weeks after delivery than were infants who were enrolled in the trial (Table I). Despite the difference in these risk factors for neonatal morbidity, infants who were treated outside PDA-TOLERATE had a similar or significantly lower incidence of late neonatal morbidity than infants enrolled in the trial (Table 1).

As a group, the infants who were treated outside the trial due to LPE were treated at an earlier postnatal age and had earlier ductus constriction than infants enrolled in PDA-TOLERATE (Table 1). Because recent controlled quality improvement projects (2–4) and controlled observational studies (5) have reported that early PDA constriction and early PDA treatment (before day 6) are associated with a lower incidence of late neonatal respiratory morbidity, we examined the infants who were treated outside the trial to see if infants treated

before postnatal day 6 had a lower incidence of late morbidity than infants treated day 6 (Table 2). Infants whose PDAs were treated before day 6 were born at a younger gestational age than those who were treated at 6 days (Table 2). After adjusting for differences in gestational age and other demographic variables that have been associated with late neonatal respiratory morbidity, (see Methods) we found that infants who were treated before day 6 had a significantly lower incidence of BPD [Odds Ratio (95% confidence interval): 0.277 (0.113, 0.681)], combined outcome BPD or Death, [0.256 (0.105, 0.625)] and combined outcome Needing Home Oxygen or Death [0.220 (0.087, 0.560)] (Table 3; available at www.jpeds.com).

Discussion

We found that eligible infants who were not enrolled in PDA-TOLERATE due to LPE were less mature and needed more respiratory support than infants who were enrolled in the trial (Table 1). However, LPE infants (who were treated outside the trial) had a similar or significantly lower incidence of late neonatal morbidity and mortality compared with enrolled infants in spite of their relative immaturity and their greater need for respiratory support (Table 1). We hypothesize that this paradoxical finding could be due to the earlier PDA treatment and ductus constriction that occurred in infants who were treated outside of the trial (Table 1). Recent controlled quality improvement studies (2–4) and epidemiologic studies (6, 7) have reported an association between early PDA treatment and lower rates of BPD and neonatal morbidity. In our study, infants who were treated outside the trial, before day 6, had a lower incidence of late neonatal respiratory morbidity than infants who were treated after day 6 (Table 3). This occurred despite the fact that infants who were treated before day 6 were less mature and had more complications (eg, bacteremia and necrotizing enterocolitis) than infants who were treated after day 6 (Table 2).

Our study has several limitations. The study coordinators were aware of the treatments the infants received. This may have affected some of the study outcomes. Data was unavailable for infants who were treated outside of the study from one of the 17 study sites, though that site only contributed 2 infants to the parent PDA-TOLERATE trial. Additionally, the relatively small number of infants in each of the study groups also may have limited the overall power of our analyses. Last, unmeasured differences between the groups, that could have affected the outcomes, may have existed despite the fact that infants enrolled in PDA-TOLERATE and infants treated outside the trial were admitted concurrently and met the same eligibility criteria. For example, infants enrolled in the trial needed both physician and parental consent to enter the trial (22% of the families declined to enroll their infants). Because the parents of infants who were treated outside of the trial were never given the opportunity to decline trial entry, the number of infants included in the LPE group may be spuriously elevated. The absence of a parental declination step in the LPE group also may have altered the demographic composition of the group, as evidenced by the higher number of non-Caucasian infants in that group (8)).

Although the timing of PDA treatment appears to influence neonatal outcomes in our study, it does not necessarily mean that earlier PDA treatment leads to less morbidity. The study was not primarily designed to evaluate the effects of treatment before and after 6 days; and,

even though we adjusted our analyses for demographic variables that differed between the two “time-of-treatment” subgroups (Table 2 and Table 3), there may have been unmeasured infant characteristics that led physicians to think that infants treated early were more “PDA-compromised” than those treated late. Our findings underscore the need for appropriate randomized controlled trials specifically designed to examine the benefits or risks of PDA treatment initiated shortly after birth compared with conservative approaches that delay PDA treatment beyond the first week.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported by grants from the Gerber Foundation, U.S. Public Health Service National Heart, Lung and Blood Institute (**HL109199**), National Center for Advancing Translational Sciences, National Institutes of Health, through (**UL1 TR001872**, **UL1 TR000004** and UL1TR001873), and a gift from the Jamie and Bobby Gates Foundation. The authors declare no conflicts of interest.

Abbreviations

PDA	patent ductus arteriosus
BPD	bronchopulmonary dysplasia
BPD or Death	bronchopulmonary dysplasia or death before 36 weeks
LPE	lack of physician equipoise
PDA-TOLERATE	the PDA: TO LEave it alone or Respond And Treat Early Trial

References

1. Clyman RI, Liebowitz M, Kaempf J, Erdevé O, Bulbul A, Hakansson S, et al. PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. *J Pediatr*. 2019;205:41–8 e6. [PubMed: 30340932]
2. Liebowitz M, Clyman RI. Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes. *J Pediatr*. 2017;187:119–26 e1. [PubMed: 28396025]
3. Kaempf JW, Wu YX, Kaempf AJ, Kaempf AM, Wang L, Grunkemeier G. What happens when the patent ductus arteriosus is treated less aggressively in very low birth weight infants? *J Perinatol*. 2012;32:344–8. [PubMed: 21818064]
4. Kaempf JW, Huston RK, Wu YX, Kaempf AJ, Wang L, Grunkemeier G, et al. Permissive tolerance of the patent ductus arteriosus may increase the risk of chronic lung disease. *Research and Reports in Neonatology*. 2013;3:5–10.
5. Schena F, Francescato G, Cappelleri A, Picciolli I, Mayer A, Mosca F, et al. Association between Hemodynamically Significant Patent Ductus Arteriosus and Bronchopulmonary Dysplasia. *J Pediatr*. 2015;166:1488–92. [PubMed: 25882876]
6. Jensen EA, Dysart KC, Gantz MG, Carper B, Higgins RD, Keszler M, et al. Association between Use of Prophylactic Indomethacin and the Risk for Bronchopulmonary Dysplasia in Extremely Preterm Infants. *J Pediatr*. 2017; 186:34–40 e2. [PubMed: 28258737]

7. Hagadorn JI, Bennett MV, Brownell EA, Payton KSE, Benitz WE, Lee HC. Covariation of Neonatal Intensive Care Unit-Level Patent Ductus Arteriosus Management and In-Neonatal Intensive Care Unit Outcomes Following Preterm Birth. *J Pediatr.* 2018;203:225–33 e1. [PubMed: 30243544]
8. Natale JE, Lebet R, Joseph JG, Ulysse C, Ascenzi J, Wypij D, et al. Racial and Ethnic Disparities in Parental Refusal of Consent in a Large, Multisite Pediatric Critical Care Clinical Trial. *J Pediatr.* 2017;184:204–8 e1. [PubMed: 28410087]
9. Fenton TR, Kim JH. A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatr.* 2013;13:59. [PubMed: 23601190]
10. Bell MJ, Ternberg JL, Feigin RD, Keating JP, Marshall R, Barton L, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. *Ann Surg.* 1978;187:1–7. [PubMed: 413500]

Table 1:

Comparison of prenatal and neonatal characteristics of infants enrolled in the PDA-TOLERATE trial with those who were eligible for the trial but were not enrolled because the infant's medical team wanted to treat the PDA outside of the study.

	PDA-TOLERATE enrollees (n=202)	Infants NOT enrolled (infants treated due to physician preference) (n=137)	p- value ^a
Prenatal Variables:			
Maternal age – years (m±sd)	29.4±6.4	28.7±6.0	
Multiple gestation - %	32	36	
Premature rupture of membranes - %	20	21	
Preeclampsia - %	18	19	
Chorioamnionitis - %	16	14	
Diabetes - %	4	7	
Caesarian section - %	69	76	
Betamethasone 24 hours - %	64	53	0.030
Neonatal Variables:			
Gestation – weeks (m±sd)	25.8±1.2	25.5±1.2	0.017
Gestation ≥ 25 weeks - %	52	61	0.108
Birthweight - grams (m±sd)	800±169	785±179	
Small for Gestation - %	7	9	
Male - %	45	47	
Caucasian - %	52	35	0.002
Apgar (10-minutes) ≥ 6 - %	93	96	
Surfactant - %	91	97	0.028
Dopamine during 1 st 72 hours after birth - %	34	21	0.010
Intubated in Delivery Room - %	69	85	0.001
Intubated at 24 hours - %	64	74	0.076
Intubated at 8 days - %	50	64	0.011
Intubated at 15 days - %	47	63	0.002
Postnatal steroids - %	45	49	
Early onset bacteremia - %	4	4	
Late bacteremia - %	26	18	0.114
NEC or GI perforation -%	19	16	
Age when ductus constricted (small or closed) – days (median (IQR))	22 (14–46)	11 (7–21)	<0.001
Age at enrollment (PDA-TOLERATE) or Decision to treat PDA – days (m±sd)	8.2±2.2	5.4±3.3	<0.001
Neonatal Outcomes:			
Death - %	14	3	<0.001
BPD - %	51	53	

	PDA-TOLERATE enrollees (n=202)	Infants NOT enrolled (infants treated due to physician preference) (n=137)	p- value ^a
BPD or Death - %	57	55	
Home O2 - %	32	24	
Home O2 or Death - %	41	27	0.005
ROP treated - %	18	20	

Values in the table are percentages, mean \pm standard deviations, or median (interquartile range)

^ap-value are presented only for values <0.150

IQR, interquartile range

Small for Gestation, birthweight-for-gestational-age z-scores were obtained using the growth curves from Fenton et al (9);

NEC or GI perforation, necrotizing enterocolitis (Bell's classification II or greater (10)) or spontaneous gastrointestinal perforation;

Late bacteremia, culture-positive bacteremia that was not associated with NEC or GI perforation; *Death*, death any time during the neonatal hospitalization;

BPD, bronchopulmonary dysplasia was defined as oxygen use at 36 weeks postmenstrual age;

BPD or Death, BPD or Death before 36 weeks;

Home O2 or Death, infant died prior to hospital discharge or required supplemental oxygen when discharged

ROP, retinopathy of prematurity requiring laser or bevacizumab treatment

Table 2:

Comparison of prenatal and neonatal characteristics of infants not enrolled in the PDA-TOLERATE trial (due to the medical team's preference for PDA treatment) who were treated either day 5 or day 6.

	Infants NOT enrolled due to physician preference		p-value ^a
	treated day 6 (n=52)	treated day 5 (n=85)	
Prenatal Variables:			
Maternal age – years (m±sd)	28.1±5.7	29.0±6.2	
Multiple gestation - %	35	36	
Premature rupture of membranes - %	26	18	
Preeclampsia - %	22	18	
Chorioamnionitis - %	10	17	
Diabetes - %	4	9	
Caesarian section - %	69	80	
Betamethasone 24 hours - %	58	49	
Neonatal Variables:			
Gestation – weeks (m±sd)	25.8±1.2	25.3±1.2	0.021
Gestation < 25 weeks - %	48	69	0.013
Birthweight - grams (m±sd)	824±177	762±177	0.049
Small for Gestation - %	4	12	0.112
Male - %	48	46	
Caucasian - %	46	28	0.033
Apgar (10-minutes) < 6 - %	92	98	0.138
Surfactant - %	96	98	
Dopamine during 1 st 72 hours after birth - %	14	26	0.094
Intubated in Delivery Room - %	81	87	
Intubated at 24 hours - %	73	74	
Intubated at 8 days - %	63	63	
Intubated at 15 days - %	54	68	0.091
Postnatal steroids - %	44	51	
Early onset bacteremia - %	0	6	0.075
Late bacteremia - %	10	24	0.038
NEC or GI perforation - %	8	21	0.035
Age when ductus constricted (small or closed) – days (median (IQR))	16 (11–16)	8 (6–19)	<0.001
Age at Decision to treat PDA – days (m±sd)	8.8±2.8	3.3±1.2	<0.001
Neonatal Outcomes:			
Death - %	6	1	0.125
BPD - %	63	48	0.114
BPD or Death - %	65	49	0.072

	Infants NOT enrolled due to physician preference		p-value ^a
	treated day 6 (n=52)	treated day 5 (n=85)	
Home O2 - %	34	19	0.048
Home O2 or Death - %	38	20	0.020
ROP treated - %	13	23	

Values in the table are percentages, mean \pm standard deviations, or median (interquartile range)

^a p-value are presented only for values <0.150

IQR, interquartile range

Small for Gestation, birthweight-for-gestational-age z-scores were obtained using the growth curves from Fenton et al (9);

NEC or GI perforation, necrotizing enterocolitis (Bell's classification II or greater (10)) or spontaneous gastrointestinal perforation;

Late bacteremia, culture-positive bacteremia that was not associated with NEC or GI perforation; *Death*, death any time during the neonatal hospitalization;

BPD, bronchopulmonary dysplasia was defined as oxygen use at 36 weeks postmenstrual age;

BPD or Death, BPD or Death before 36 weeks;

Home O2 or Death, infant died prior to hospital discharge or required supplemental oxygen when discharged

ROP, retinopathy of prematurity requiring laser or bevacizumab treatment

Table 3; online only:

Neonatal Outcomes among infants who were not enrolled in the PDA-TOLERATE trial and received open-label PDA treatment due to physician preference: a comparison of the effects of PDA treatment on or before day 5 with treatment on or after day 6.

Outcomes	Multivariable Models (effects of PDA treatment day 5 compared with treatment day6) ^a	
	Odds Ratio (95% CI) ^b	p-value
Death	0.082 (0.005, 1.393)	0.083
BPD	0.277 (0.113, 0.681)	0.005
BPD or Death	0.256 (0.105, 0.625)	0.003
Home O2 or Death	0.220 (0.087, 0.560)	0.001

^a multivariate models were designed to compare the effects of PDA treatment before day 6 with treatment on or after day 6 on neonatal outcomes (see Methods). Variables included in the Final Models:

Death: *Postnatal age at treatment, Gestational Age, Betamethasone 24 hours, SGA, Dopamine during first 72 hours after birth, and Caucasian race.*

BPD: *Postnatal age at treatment, Gestational Age, Betamethasone 24 hours, and SGA.*

BPD and Death: *Postnatal age at treatment, Gestational Age, Betamethasone 24 hours, and SGA* Home O2 or Death: *Postnatal age at treatment, Gestational Age, Betamethasone 24 hours, and SGA*

^b Odds ratio and 95% confidence interval (CI) of PDA treatment postnatal day 5 compared with treatment day6.

BPD, bronchopulmonary dysplasia was defined as oxygen use at 36 weeks postmenstrual age;

BPD or Death, BPD or Death before 36 weeks;

Death, death any time during the neonatal hospitalization;

Home O2 or Death, infant died prior to hospital discharge or required supplemental oxygen when discharged